Share This
table started by
bioventurist for the BioVenturist Base
There is no user-contributed description yet.
Add More Topics
Save this view to a base, or just for yourself.
780 Indication topics matching:
Filter this Collection
Sort by
Date Added
↓
|
|
|
|||||
|---|---|---|---|---|---|---|
| x Therapeutics | x Disease | x Phase of development | x Notes | |||
| x name | x image | x article | ||||
| Panitumumab |
Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).
Panitumumab is manufactured by Amgen and marketed as Vectibix....
|
Colorectal cancer | On the market | |||
| Pegfilgrastim |
Pegfilgrastim is a immunostimulator which functions as a PEGylated granulocyte colony-stimulating factor. Amgen manufactures pegfilgrastim under the brand name Neulasta.
|
Febrile neutropenia | On the market | |||
| Cinacalcet |
|
Cinacalcet (INN) is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade...
|
Secondary hyperparathyroidism | On the market | ||
| Darbepoetin alfa |
Darbepoetin alfa (rINN) (pronounced /dɑrbəˈpɔɪtɨn/) is a synthetic form of erythropoietin. It stimulates erythropoiesis (increases red blood cell levels) and is used to treat anemia, commonly associated with chronic renal failure and cancer...
|
Anemia | On the market | |||
| Etanercept |
|
Etanercept (Enbrel) is a drug that treats autoimmune diseases by interfering with the TNF receptor (a part of the immune system) by acting as a TNF inhibitor.
Etanercept is a fusion protein produced through expression of recombinant DNA. That is, it...
|
Rheumatoid arthritis | On the market | ||
| Palifermin |
Palifermin (Kepivance, Biovitrum) is a human recombinant keratinocyte growth factor (KGF) produced in Escherichia coli.
Palifermin costs approximately 5,000 Euros per treatment for a 70 kg patient
When patients with blood cancers undergo high dose...
|
On the market | ||||
| Anakinra |
|
Anakinra (Kineret) is a drug used to treat rheumatoid arthritis.
Anakinra is an interleukin-1 (IL-1) receptor antagonist. Anakinra blocks the biologic activity of naturally occurring IL-1, including inflammation and cartilage degradation associated...
|
On the market | |||
| Filgrastim |
|
Filgrastim is a granulocyte colony-stimulating factor (G-CSF) analog used to stimulate the proliferation and differentiation of granulocytes. It is produced by recombinant DNA technology. The gene for human granulocyte colony-stimulating factor is...
|
Neutropenia | On the market | ||
| TNKase | Myocardial infarction | On the market | ||||
| Non-Small Cell Lung Carcinoma | On the market | |||||
| Abelcet | Fungal Infections | On the market | ||||
| Amphotec | Fungal Infections | On the market | ||||
| Ambisome | Fungal Infections | On the market | ||||
| DaunoXome | Kaposi's sarcoma | On the market | ||||
| Depocyt | Cancer | On the market | ||||
| Epaxal Berna | Hepatitis A | On the market | ||||
| Inflexal V Berna | Influenza | On the market | ||||
| Myocet | Breast cancer | On the market | ||||
| Visudyne | Age-Related Macular Degeneration | On the market | ||||
| Estrasorb | Menopause | On the market | ||||
| Adagen | Immunodeficiency | On the market | ||||
| Oncaspar | Leukemia | On the market | ||||
| PEGASYS |
Pegylated interferon alfa-2a (40 kDa; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The additon of polyethylene...
|
Hepatitis C | On the market | |||
| PEG-Intron | Hepatitis C | On the market | ||||
| Macugen | Wet Age-Related Macular Degeneration | On the market | ||||
| Rituximab |
Rituximab, sold under the trade names Rituxan and MabThera, is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of B cells. Rituximab is used in the treatment of many lymphomas, leukemias, and some...
|
Rheumatoid arthritis | On the market | |||
| Rituximab |
Rituximab, sold under the trade names Rituxan and MabThera, is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of B cells. Rituximab is used in the treatment of many lymphomas, leukemias, and some...
|
Non-Hodgkin lymphoma | On the market | |||
| Trastuzumab |
|
Trastuzumab (Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor.
The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell to inside the cell, and turn...
|
Breast cancer | On the market | ||
| Palivizumab |
Palivizumab (brand name Synagis or Abbosynagis) is a monoclonal antibody produced by recombinant DNA technology. It is used in the prevention of Respiratory Syncytial Virus (RSV) infections. It is recommended for certain infants that are high-risk ...
|
Human respiratory syncytial virus | On the market | |||
| Adalimumab |
|
Adalimumab (HUMIRA, Abbott) is the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. Like infliximab and etanercept, adalimumab binds to TNFα, preventing it from activating TNF receptors; adalimumab was...
|
Chronic Childhood Arthritis | On the market | ||
| Adalimumab |
|
Adalimumab (HUMIRA, Abbott) is the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. Like infliximab and etanercept, adalimumab binds to TNFα, preventing it from activating TNF receptors; adalimumab was...
|
Psoriasis | On the market | ||
| Adalimumab |
|
Adalimumab (HUMIRA, Abbott) is the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. Like infliximab and etanercept, adalimumab binds to TNFα, preventing it from activating TNF receptors; adalimumab was...
|
Psoriatic arthritis | On the market | ||
| Adalimumab |
|
Adalimumab (HUMIRA, Abbott) is the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. Like infliximab and etanercept, adalimumab binds to TNFα, preventing it from activating TNF receptors; adalimumab was...
|
Ankylosing spondylitis | On the market | ||
| Adalimumab |
|
Adalimumab (HUMIRA, Abbott) is the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. Like infliximab and etanercept, adalimumab binds to TNFα, preventing it from activating TNF receptors; adalimumab was...
|
Rheumatoid arthritis | On the market | ||
| Adalimumab |
|
Adalimumab (HUMIRA, Abbott) is the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. Like infliximab and etanercept, adalimumab binds to TNFα, preventing it from activating TNF receptors; adalimumab was...
|
Crohn's disease | On the market | ||
| Fluorouracil |
|
Fluorouracil (5-FU or f5U) (Adrucil, Efudex, Fluoroplex) is a pyrimidine analog, which is used as a drug in the treatment of cancer. It belongs to the family of drugs called antimetabolites. It is typically administered with leucovorin.
The...
|
Colorectal cancer | On the market | Indicated for first or second line treatment for metastatic carcinoma of the colon or rectum | |
| Bevacizumab |
Bevacizumab (trade name Avastin, Genentech/Roche) is a humanized monoclonal antibody that recognises and blocks vascular endothelial growth factor (VEGF). VEGF is a chemical signal that stimulates the growth of new blood vessels (angiogenesis)....
|
|||||
| Carboplatin |
|
Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers). It was introduced in the late 1980s and has since gained popularity in clinical treatment due to its vastly reduced side...
|
Non-Small Cell Lung Carcinoma | On the market | Indicated for unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer. | |
| Paclitaxel |
|
Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific Yew...
|
||||
| Bevacizumab |
Bevacizumab (trade name Avastin, Genentech/Roche) is a humanized monoclonal antibody that recognises and blocks vascular endothelial growth factor (VEGF). VEGF is a chemical signal that stimulates the growth of new blood vessels (angiogenesis)....
|
|||||
| Paclitaxel |
|
Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific Yew...
|
Breast cancer | On the market | Indicated for patients who have not received chemotherapy for metastatic HER2-negative breast cancer. | |
| Bevacizumab |
Bevacizumab (trade name Avastin, Genentech/Roche) is a humanized monoclonal antibody that recognises and blocks vascular endothelial growth factor (VEGF). VEGF is a chemical signal that stimulates the growth of new blood vessels (angiogenesis)....
|
|||||
| Abciximab |
Abciximab (previously known as c7E3 Fab), manufactured by Centocor and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent...
|
Ischemia | On the market | |||
| Omalizumab |
|
Omalizumab (Xolair, Genentech / Novartis) is a humanized antibody drug approved for patients with moderate-to-severe or severe allergic asthma, which is caused by hypersensitivity reactions to certain harmless environmental substances. Omalizumab's...
|
Asthma | On the market | ||
| Alemtuzumab |
|
Alemtuzumab (marketed as Campath, MabCampath or Campath-1H) is a monoclonal antibody used in the treatment of chronic lymphocytic leukemia (CLL), cutaneous T cell lymphoma (CTCL) and T-cell lymphoma.
Alemtuzumab targets CD52, a protein present on...
|
Chronic lymphocytic leukemia | On the market | ||
| Basiliximab |
|
Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants. It is a Novartis...
|
Transplant rejection | On the market | ||
| Cetuximab |
Cetuximab (IMC-C225 -- marketed under the name Erbitux) is a chimeric (mouse/human) monoclonal antibody, an epidermal growth factor receptor (EGFR) inhibitor, given by intravenous infusion for treatment of metastatic colorectal cancer and head and...
|
Colorectal cancer | On the market | |||
| Ibritumomab tiuxetan |
Ibritumomab tiuxetan, sold under the trade name Zevalin, is a monoclonal antibody radioimmunotherapy treatment for some forms of B cell non-Hodgkin's lymphoma, a myeloproliferative disorder of the lymphatic system. The drug uses the monoclonal mouse...
|
Non-Hodgkin lymphoma | On the market | |||
| Gemtuzumab ozogamicin |
Gemtuzumab ozogamicin (marketed by Wyeth as Mylotarg) is a monoclonal antibody used to treat acute myelogenous leukemia.
It is a monoclonal antibody to CD33 linked to a cytotoxic agent from the class of calicheamicins. CD33 is expressed in most...
|
Acute myeloid leukemia | On the market | |||
| Efalizumab |
Efalizumab (trade name Raptiva, Genentech, Merck Serono) is a medication designed to treat psoriasis. As its name implies, it is a recombinant humanized monoclonal antibody that binds to CD11a and acts as an immunosuppressant. It is administered...
|
Psoriasis | On the market | |||
| Tositumomab |
Tositumomab is a monoclonal antibody derived from immortalized mouse cells. It is a IgG2a anti-CD20 antibody and is covalently bound to I. I emits both beta and gamma radiation and decays with a half-life of 8 days.
Clinical trials have established...
|
Follicular lymphoma | On the market | |||
| Muromonab |
Muromonab-CD3 (generic name) is a monoclonal antibody (mAb), also known as Orthoclone OKT3 (Brand name). It is a mouse-derived (murine) monoclonal antibody that specifically binds to the CD3 (T3) protein found on the surface of T cells.
Of...
|
Transplant rejection | On the market | |||
| Edrecolomab |
Edrecolomab (MAb17-1A, trade name Panorex) is a chimeric mouse/human monoclonal antibody to the cell-surface glycoprotein EpCAM (17-1A), which is expressed on epithelial tissues and on various carcinomas.
Preliminary studies had shown promise of a...
|
Colorectal cancer | Phase III Clinical Trial | |||
| Daclizumab |
Daclizumab (trade name Zenapax) was a therapeutic humanized monoclonal antibody to the alpha subunit of the IL-2 receptor of T cells. It was used to prevent rejection in organ transplantation, especially in kidney transplants.
In April 2008, its...
|
Transplant rejection | On the market | |||
| SGN-40 | Multiple myeloma | Phase III Clinical Trial | ||||
| SGN-40 | Non-Hodgkin lymphoma | Phase III Clinical Trial | ||||
| Lintuzumab |
Lintuzumab is a humanized monoclonal antibody used in the treatment of cancer.
|
Myelodysplastic syndrome | Phase I Clinical Trial | |||
| Lintuzumab |
Lintuzumab is a humanized monoclonal antibody used in the treatment of cancer.
|
Acute myeloid leukemia | Phase I Clinical Trial | |||
| SGN-35 | Hodgkin's lymphoma | Phase I Clinical Trial | ||||
| SGN-70 | Autoimmune Disease | Pre-clinical development | ||||
| SGN-75 | Renal Cancer | Pre-clinical development | ||||
| Breast cancer | Awaiting Approval | |||||
